Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age

Abstract. The regional cerebral metabolic rate of [11C]N-methyl-4-piperidyl acetate, which is nearly proportional to regional cerebral acetylcholinesterase (AChE) activity, was measured by dynamic positron emission tomography in 20 healthy subjects with a wide age range (24–89 years). Quantitative measurement was achieved using a kinetic model which consisted of arterial plasma and cerebral tissue compartments. The plasma input function was obtained using thin-layer chromatography and an imaging phosphor plate system at frequent sampling intervals to catch the rapid metabolism of the tracer in the blood. The distribution of the rate constant k3, an index of AChE activity, agreed well with reported post-mortem AChE distribution in the cerebral cortex (0.067–0.097 min–1) and thalamus (0.268 min–1), where AChE activity was low to moderate. The k3 values in the striatum and cerebellum, where AChE activity was very high, did not respond linearly to AChE activity because of increased flow dependency. No significant effect of age was found on AChE activity of the cerebral cortex, suggesting that the ascending central cholinergic system is preserved in normal aging. This study has shown that quantitative measurement of enzyme activity in the living brain is possible through appropriate modelling of tracer kinetics and accurate measurement of the input function. The method should be applicable to patients with Alzheimer’s disease and those with other kinds of dementia whose central cholinergic system has been reported to be disturbed.

[1]  K. Davis,et al.  Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic Deficits , 1995, Journal of neurochemistry.

[2]  E. Hoffman,et al.  TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.

[3]  K. Fukushi,et al.  Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. , 1994, Nuclear medicine and biology.

[4]  Hitoshi Shinotoh,et al.  Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease , 1997, The Lancet.

[5]  F. Shishido,et al.  Evaluation of Regional Differences of Tracer Appearance Time in Cerebral Tissues Using [15O]Water and Dynamic Positron Emission Tomography , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[7]  E. Perry,et al.  Molecular Forms of Acetylcholinesterase and Butyrylcholinesterase in the Aged Human Central Nervous System , 1986, Journal of neurochemistry.

[8]  Application of Bioimage Analyzer on Drug Metabolism Studies Using Thin Layer Chromatography. (II). Direct Development of Plasma Samples Containing (14C)Indomethacin and Its Metabolites. , 1993 .

[9]  K Kosaka,et al.  [A biochemical study of cholinergic neurons of the post-mortem brains from the patients with Alzheimer-type dementia]. , 1984, Rinsho shinkeigaku = Clinical neurology.

[10]  H. Akaike A new look at the statistical model identification , 1974 .

[11]  M. Iyo,et al.  In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog , 1994, Brain Research.

[12]  S Grootoonk,et al.  Performance Evaluation of the Positron Scanner ECAT EXACT , 1992, Journal of computer assisted tomography.

[13]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[14]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[15]  D. Kuhl,et al.  In vivo studies of acetylcholinesterase activity using a labeled substrate, N‐[11C]methylpiperdin‐4‐yl propionate ([11C]PMP) , 1996, Synapse.

[16]  S. Pappatà,et al.  In vivo visualization of acetylcholinesterase with positron emission tomography. , 1993, Neuroreport.

[17]  H. Namba,et al.  Lesion of the nucleus basalis magnocellularis does not affect cerebral cortical blood flow in rats , 1991, Neuroscience Research.

[18]  Y. Iwadate,et al.  Quantifying brain tumor blood flow by the microsphere model with N-isopropyl-p-[123I]iodoamphetamine super-early SPECT , 1996, Annals of nuclear medicine.

[19]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[20]  S. Pappatà,et al.  In Vivo Imaging of Human Cerebral Acetylcholinesterase , 1996, Journal of neurochemistry.

[21]  M. Iyo,et al.  Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.